📊 ARCT Key Takeaways
Is Arcturus Therapeutics Holdings Inc. (ARCT) a Good Investment?
Arcturus Therapeutics is a pre-revenue pharmaceutical company burning significant cash despite maintaining a strong balance sheet with $230.9M in cash. The company is unprofitable with negative operating margins of -93% and deteriorating cash flows, requiring careful monitoring of cash runway and clinical trial progress to justify continued investment.
Arcturus Therapeutics has weak current fundamentals, with revenue down 46.1% year over year, deeply negative operating margin, and substantial cash burn. However, the balance sheet is unusually strong for a loss-making biotech, with $230.91M in cash, low leverage, and solid liquidity that provide meaningful operating runway while management works toward more durable revenue generation and improved operating efficiency.
Why Buy Arcturus Therapeutics Holdings Inc. Stock? ARCT Key Strengths
- Substantial cash position of $230.9M provides runway for development activities
- Strong balance sheet with low debt-to-equity ratio of 0.07x and excellent liquidity (current ratio 6.64x)
- Improving net loss trajectory year-over-year despite revenue decline, suggesting cost control efforts
- Very strong liquidity, with a 6.64x current and quick ratio supported by $230.91M in cash
- Low balance-sheet leverage, with debt-to-equity of just 0.07x and only $15.00M in long-term debt
- Net loss and diluted EPS improved year over year despite continued operating pressure
ARCT Stock Risks: Arcturus Therapeutics Holdings Inc. Investment Risks
- Severe revenue decline of 46.1% YoY indicates significant commercial challenges or product disappointments
- Massive negative operating cash flow of -$74.3M annually with negative FCF margin of -90.8% unsustainable long-term
- Operating margin of -93% and net margin of -80.2% demonstrate the company remains deeply unprofitable with no clear path to profitability
- Revenue fell 46.1% year over year, indicating weak growth quality and likely dependence on lumpy or non-recurring revenue sources
- Core profitability remains poor, with a -93.0% operating margin and -80.2% net margin
- Free cash flow was -$74.50M, so sustained cash burn could materially reduce financial flexibility if revenue does not recover
Key Metrics to Watch
- Quarterly cash burn rate and cash runway remaining
- Revenue trajectory and any new product commercialization success
- Operating expense trends and timing to profitability milestones
- Quarterly revenue consistency and whether top-line growth becomes recurring rather than episodic
- Operating cash burn and free cash flow relative to the current cash balance
Arcturus Therapeutics Holdings Inc. (ARCT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.64x current ratio provides a solid financial cushion.
ARCT Profit Margin, ROE & Profitability Analysis
ARCT vs Healthcare Sector: How Arcturus Therapeutics Holdings Inc. Compares
How Arcturus Therapeutics Holdings Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arcturus Therapeutics Holdings Inc. Stock Overvalued? ARCT Valuation Analysis 2026
Based on fundamental analysis, Arcturus Therapeutics Holdings Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arcturus Therapeutics Holdings Inc. Balance Sheet: ARCT Debt, Cash & Liquidity
ARCT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arcturus Therapeutics Holdings Inc.'s revenue has grown significantly by 702% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.12 indicates the company is currently unprofitable.
ARCT Revenue Growth, EPS Growth & YoY Performance
ARCT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $17.2M | -$6.9M | $-0.26 |
| Q2 2025 | $28.3M | -$9.2M | $-0.34 |
| Q1 2025 | $29.4M | -$14.1M | $-0.52 |
| Q3 2024 | $41.7M | -$6.9M | $-0.26 |
| Q2 2024 | $10.5M | -$1.8M | $-0.07 |
| Q1 2024 | $38.0M | -$26.8M | $-1.00 |
| Q3 2023 | $13.4M | -$16.2M | $-0.61 |
| Q2 2023 | $10.5M | -$1.8M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arcturus Therapeutics Holdings Inc. Dividends, Buybacks & Capital Allocation
ARCT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arcturus Therapeutics Holdings Inc. (CIK: 0001768224)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARCT
What is the AI rating for ARCT?
Arcturus Therapeutics Holdings Inc. (ARCT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARCT's key strengths?
Claude: Substantial cash position of $230.9M provides runway for development activities. Strong balance sheet with low debt-to-equity ratio of 0.07x and excellent liquidity (current ratio 6.64x). ChatGPT: Very strong liquidity, with a 6.64x current and quick ratio supported by $230.91M in cash. Low balance-sheet leverage, with debt-to-equity of just 0.07x and only $15.00M in long-term debt.
What are the risks of investing in ARCT?
Claude: Severe revenue decline of 46.1% YoY indicates significant commercial challenges or product disappointments. Massive negative operating cash flow of -$74.3M annually with negative FCF margin of -90.8% unsustainable long-term. ChatGPT: Revenue fell 46.1% year over year, indicating weak growth quality and likely dependence on lumpy or non-recurring revenue sources. Core profitability remains poor, with a -93.0% operating margin and -80.2% net margin.
What is ARCT's revenue and growth?
Arcturus Therapeutics Holdings Inc. reported revenue of $82.0M.
Does ARCT pay dividends?
Arcturus Therapeutics Holdings Inc. does not currently pay dividends.
Where can I find ARCT SEC filings?
Official SEC filings for Arcturus Therapeutics Holdings Inc. (CIK: 0001768224) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARCT's EPS?
Arcturus Therapeutics Holdings Inc. has a diluted EPS of $-2.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ARCT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Arcturus Therapeutics Holdings Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ARCT stock overvalued or undervalued?
Valuation metrics for ARCT: ROE of -30.7% (sector avg: 15%), net margin of -80.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ARCT stock in 2026?
Our dual AI analysis gives Arcturus Therapeutics Holdings Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARCT's free cash flow?
Arcturus Therapeutics Holdings Inc.'s operating cash flow is $-74.3M, with capital expenditures of $230.0K. FCF margin is -90.8%.
How does ARCT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -80.2% (avg: 12%), ROE -30.7% (avg: 15%), current ratio 6.64 (avg: 2).